Ann Arbor’s NeuMoDx Molecular Inc., which designs and develops molecular diagnostic solutions for hospital and clinical reference laboratories, has been acquired by a company based in the Netherlands.
Qiagen N.V. Thursday announced the acquisition of the remaining 80.1 percent of NeuMoDx for $248 million in cash. The move adds to Qiagen’s portfolio of automated molecular testing solutions. Qiagen had purchased a 19.9 percent stake in NeuMoDx along with the right to acquire the remaining stake in 2018.
“NeuMoDx devices offer labs with medium to high throughput exactly what they need,” says Thierry Bernard, CEO of Qiagen. “Labs want compact systems with true random access, fast turnaround time, full automation, and comprehensive menus. The full integration of the NeuMoDx systems will allow QIAGEN to address laboratory needs in almost any setting for molecular diagnostics. We are excited to be able to build on NeuMoDx’s success and will jointly work on expanding our product portfolio and global distribution.”
The transaction was completed after Qiagen received U.S. regulatory clearance for the full acquisition. As part of the 2018 agreement, Qiagen has distributed the high-throughput NeuMoDx 288 and the medium-throughput NeuMoDx 96 platforms in Europe and other international markets.
“Becoming a part of QIAGEN allows us to take our successes at NeuMoDx to the next level,” says Jeff Williams, chairman and CEO of NeuMoDx. “We have built a broad testing portfolio and created strong customer enthusiasm around the world with our device’s unique combination of speed, flexibility, throughput, and ease of use. This transaction is a testament to the achievements of the entire NeuMoDx team, and we are excited to finally become a full part of the QIAGEN family.”
The NeuMoDx 288 and NeuMoDx 96 systems offer 13 CE-IVD-marked assays for different infectious diseases in Europe, including a COVID-19 test that also received FDA Emergency Use Authorization for the U.S. market. A new test for influenza, respiratory syncytial virus, and the COVID-19 virus is scheduled for launch in the fourth quarter of 2020.
NeuMoDx’s devices have a fast, fully automated turnaround time, delivering insights in an hour; allow clinical molecular diagnostic laboratories to process larger volumes and deliver faster insights; drive a growing list of in vitro diagnostic tests thanks to the devices’ flexibility; and enable processing of commercial and laboratory-developed tests.
Qiagen’s sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. It employs more than 5,200 people in more than 35 locations worldwide.
